Advancing Immunotherapy Testing with Functional Antigen Specific T Cells | RoukenBio & BioIVT

Описание: Immunotherapy has transformed cancer treatment, but persistent challenges, such as T cell exhaustion, limited persistence, and variability in response, continue to impact therapeutic success. Antigen-specific T cells, central to adaptive immunity, offer a powerful platform for evaluating and optimising immunotherapies.

This webinar will provide a concise overview of strategies for generating TCR-T and endogenous antigen-specific T cells, comparing these approaches with CAR-T and other modalities, and addressing key hurdles in specificity, durability, and exhaustion. We will highlight RoukenBio innovative capability to produce scalable banks of functional antigen-specific T cells, implement rescue strategies for exhausted phenotypes, and expand into NK cells, γδ T cells, and CAR-T platforms.

A case study will demonstrate how TCR-T cells can assess immune modulators through measurable endpoints such as IFN-γ secretion and CD137 activation, delivering actionable insights for drug development. In collaboration with BioIVT, whose robust immune cell solutions form the foundational starting material for these advancements, with a commitment to Quality and Operational Excellence, ensuring researchers receive highly reliable and ethically sourced PBMCs and purified cell subsets. Learn about BioIVT’s Donor Management capabilities, featuring a diverse and well-characterized donor base (including HLA-typed donors), along with custom processing and collection processing and collection services optimized for client demand.

Join us to explore next-generation solutions that enhance immunotherapy evaluation and accelerate translational research.

Learning Objectives:

Understand the role of antigen-specific T cells in adaptive immunity and their application in immunotherapy testing.

Compare TCR-T and endogenous T cell generation strategies, including challenges and rescue approaches for exhaustion.

Learn how RoukenBio and BioIVT capabilities enable scalable, flexible platforms for translational research and collaboration for researchers across auto-immunity, immuno-oncology and complex cell therapy development.